Small Biotech Innovation Act
Latest Action
Read twice and referred to the Committee on Finance.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Small Biotech Innovation Act (S.5029) was a Senate bill introduced in the 118th Congress aimed at supporting small biotechnology companies. The bill was referred to the Senate Committee on Finance after being read twice but ultimately failed or expired without further action. Specific provisions, funding mechanisms, or detailed policy measures are not available in the provided data, limiting a full analysis of the bill's content or intended impact.
S.5029 sought to address issues related to small biotech innovation but did not advance beyond committee referral and expired without enactment.
- The bill was introduced in the Senate during the 118th Congress and referred to the Committee on Finance.
- No official summary or full text is available to detail the bill's provisions or objectives.
- The bill's status is recorded as failed or expired, indicating it did not become law.
['Small biotechnology companies and startups', 'Potentially the broader health sector if innovation support was realized']
["Lack of publicly available full text and summary limits transparency and understanding of the bill's scope and mechanisms.", 'Without enacted legislation, no implementation or oversight structures were established.', 'Potential costs, funding sources, or regulatory impacts remain unknown.']
The bill was introduced in the Senate and referred to the Committee on Finance but did not progress further. The absence of additional legislative action or public documentation suggests limited legislative momentum or prioritization during the 118th Congress.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have stimulated innovation and growth in the small biotech sector, potentially influencing health research and development.', 'Failure to pass may maintain existing challenges faced by small biotech firms in accessing financial or regulatory support.']
The absence of a bill summary and full text in official records highlights a transparency gap that complicates public oversight and informed debate. Tracking the bill's referral to the Committee on Finance without further action underscores the importance of monitoring committee processes and legislative follow-through.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.